Aflibercept	0	11	B-Drug_or_compound
(	12	13	O
AVE0005	13	20	B-Drug_or_compound
)	20	21	O
:	21	22	O
an	23	25	O
alternative	26	37	O
strategy	38	46	O
for	47	50	O
inhibiting	51	61	O
tumour	62	68	B-Pathological_formation
angiogenesis	69	81	O
by	82	84	O
vascular	85	93	B-Gene_or_gene_product
endothelial	94	105	I-Gene_or_gene_product
growth	106	112	I-Gene_or_gene_product
factors	113	120	I-Gene_or_gene_product
.	120	121	O

BACKGROUND	123	133	O
:	133	134	O
Aberrant	135	143	O
angiogenesis	144	156	O
is	157	159	O
a	160	161	O
landmark	162	170	O
feature	171	178	O
in	179	181	O
cancer	182	188	B-Pathological_formation
,	188	189	O
which	190	195	O
is	196	198	O
important	199	208	O
for	209	212	O
proliferation	213	226	O
,	226	227	O
growth	228	234	O
and	235	238	O
metastasis	239	249	O
,	249	250	O
and	251	254	O
is	255	257	O
mediated	258	266	O
by	267	269	O
various	270	277	O
pro	278	281	O
-	281	282	O
angiogenic	282	292	O
factors	293	300	O
.	300	301	O

The	302	305	O
VEGF	306	310	B-Gene_or_gene_product
pathway	311	318	O
is	319	321	O
one	322	325	O
of	326	328	O
the	329	332	O
most	333	337	O
important	338	347	O
and	348	351	O
best	352	356	O
-	356	357	O
studied	357	364	O
angiogenic	365	375	O
pathways	376	384	O
.	384	385	O

Inhibition	386	396	O
of	397	399	O
this	400	404	O
pathway	405	412	O
may	413	416	O
provide	417	424	O
clinical	425	433	O
benefits	434	442	O
to	443	445	O
cancer	446	452	B-Pathological_formation
patients	453	461	B-Organism
.	461	462	O

OBJECTIVES	463	473	O
:	473	474	O
Strategies	475	485	O
to	486	488	O
inhibit	489	496	O
the	497	500	O
VEGF	501	505	B-Gene_or_gene_product
pathway	506	513	O
,	513	514	O
including	515	524	O
antibodies	525	535	O
to	536	538	O
VEGF	539	543	B-Gene_or_gene_product
,	543	544	O
antibodies	545	555	O
to	556	558	O
the	559	562	O
extracellular	563	576	O
domain	577	583	O
of	584	586	O
VEGFR	587	592	B-Gene_or_gene_product
-	592	593	I-Gene_or_gene_product
1	593	594	I-Gene_or_gene_product
or	595	597	O
VEGFR	598	603	B-Gene_or_gene_product
-	603	604	I-Gene_or_gene_product
2	604	605	I-Gene_or_gene_product
,	605	606	O
decoy	607	612	O
receptors	613	622	O
for	623	626	O
VEGF	627	631	B-Gene_or_gene_product
and	632	635	O
tyrosine	636	644	B-Drug_or_compound
kinase	645	651	I-Drug_or_compound
inhibitors	652	662	I-Drug_or_compound
of	663	665	O
VEGFRs	666	672	B-Gene_or_gene_product
,	672	673	O
are	674	677	O
summarized	678	688	O
.	688	689	O

METHODS	690	697	O
:	697	698	O
This	699	703	O
review	704	710	O
outlines	711	719	O
and	720	723	O
compares	724	732	O
the	733	736	O
latest	737	743	O
development	744	755	O
of	756	758	O
these	759	764	O
strategies	765	775	O
,	775	776	O
with	777	781	O
emphasis	782	790	O
on	791	793	O
aflibercept	794	805	B-Drug_or_compound
,	805	806	O
a	807	808	O
novel	809	814	O
decoy	815	820	O
fusion	821	827	O
protein	828	835	O
of	836	838	O
domain	839	845	O
2	846	847	O
of	848	850	O
VEGFR	851	856	B-Gene_or_gene_product
-	856	857	I-Gene_or_gene_product
1	857	858	I-Gene_or_gene_product
and	859	862	O
domain	863	869	O
3	870	871	O
of	872	874	O
VEGFR	875	880	B-Gene_or_gene_product
-	880	881	I-Gene_or_gene_product
2	881	882	I-Gene_or_gene_product
with	883	887	O
the	888	891	O
Fc	892	894	B-Protein_domain_or_region
fragment	895	903	I-Protein_domain_or_region
of	904	906	O
IgG1	907	911	B-Gene_or_gene_product
.	911	912	O

RESULTS	913	920	O
:	920	921	O
Aflibercept	922	933	B-Drug_or_compound
was	934	937	O
shown	938	943	O
to	944	946	O
have	947	951	O
early	952	957	O
clinical	958	966	O
activity	967	975	O
.	975	976	O

Multiple	977	985	O
studies	986	993	O
are	994	997	O
ongoing	998	1005	O
to	1006	1008	O
determine	1009	1018	O
the	1019	1022	O
clinical	1023	1031	O
benefits	1032	1040	O
of	1041	1043	O
aflibercept	1044	1055	B-Drug_or_compound
in	1056	1058	O
cancer	1059	1065	B-Pathological_formation
patients	1066	1074	B-Organism
.	1074	1075	O

